Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.
|Articles|April 1, 1997
The American Journal of Managed Care
- April 1997
- Volume 3
- Issue 4
Correspondence regarding, "The Three Dimensions of Managed Care Pharmacy Practice"
Author(s)Peter Gal, PharmD
Advertisement
Articles in this issue
over 29 years ago
Consideration in Pharmaceutical Conversion: Focus on Antihistaminesover 29 years ago
Issues in the Measurement of Satisfaction with Treatmentover 29 years ago
HMOs and the Efficiency of Healthcare Deliveryover 29 years ago
Abdominal Aortic Aneurysmover 29 years ago
Reducing Malpractice Risk Through More Effective CommunicationAdvertisement
Related to this article
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
The regulatory decisions reflect how advances in biomarkers and molecular medicine are reshaping both diagnosis and treatment.
Measles cases hit a year high. Here's what payers need to know about outbreak costs, MMR coverage, and plans to split the vaccine
As peptides go mainstream, the FDA's shifting rules and a fractured state patchwork leave patients navigating a largely unregulated gray market.
Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.
A large propensity-matched study linked outpatient melatonin use to a small reduction in REM sleep in children evaluated for polysomnography.
Prior authorization and compounded drugs remain top obesity care access barriers, says NYU Langone's Holly Lofton, MD.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
2
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
3
Melatonin Use Linked to Small REM Sleep Reduction in Children
4
Surrogate End Points, Drug Costs Complicate Oncology Formularies
5